Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.

[1]  D. Harper,et al.  Chapter 13: Current findings from prophylactic HPV vaccine trials. , 2006, Vaccine.

[2]  G. Zimet,et al.  Chapter 24: Psychosocial aspects of vaccine acceptability. , 2006, Vaccine.

[3]  M. Schiffman,et al.  Chapter 5: Updating the natural history of HPV and anogenital cancer. , 2006, Vaccine.

[4]  J. Cuzick,et al.  Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. , 2006, Vaccine.

[5]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[6]  Henry C Kitchener,et al.  Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. , 2006, Vaccine.

[7]  J. Little,et al.  Psychological effects of a low-grade abnormal cervical smear test result: anxiety and associated factors , 2006, British Journal of Cancer.

[8]  C. Wheeler,et al.  Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.

[9]  G. Zimet,et al.  Psychosocial aspects of vaccine acceptability , 2006 .

[10]  D. Harper,et al.  Current findings from prophylactic HPV vaccine trials , 2006 .

[11]  T. Wright,et al.  HPV vaccine introduction in industrialized countries , 2006 .

[12]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[13]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[14]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[15]  R. Verheijen,et al.  Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women , 2005, International journal of cancer.

[16]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[17]  G. Sanders,et al.  Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.

[18]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[19]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[20]  Vicki B Benard,et al.  Cervical Screening in the National Breast and Cervical Cancer Early Detection Program, 1995–2001 , 2004, Obstetrics and gynecology.

[21]  J. Cuzick,et al.  Benefit of cervical screening at different ages: evidence from the UK audit of screening histories , 2003, British Journal of Cancer.

[22]  N. Kitchin,et al.  Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. , 2002, Communicable disease and public health.

[23]  F. Aoki,et al.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.

[24]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[25]  S. Granter,et al.  Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix , 2001, Cancer.

[26]  Evan R. Myers,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .

[27]  S. Raab.  Can glandular lesions be diagnosed in pap smear cytology? , 2000, Diagnostic cytopathology.

[28]  F. Vogel.  Improving vaccine performance with adjuvants. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Vic Hasselblad,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic Abnormalities , 2000, Annals of Internal Medicine.

[30]  M. Hagensee,et al.  Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.

[31]  S. Abraham.  Human papilloma virus and cervical cancer , 1986, The Medical journal of Australia.